Blau syndrome, the prototypic auto-inflammatory granulomatous disease - PubMed (original) (raw)
Review
Blau syndrome, the prototypic auto-inflammatory granulomatous disease
Carine H Wouters et al. Pediatr Rheumatol Online J. 2014.
Abstract
Blau syndrome is a monogenic disease resulting from mutations in the pattern recognition receptor NOD2, and is phenotypically characterized by the triad of granulomatous polyarthritis, dermatitis and uveitis. This paper reviews briefly the classical clinical features of the disease, as well as more recently described extra-triad symptoms. From an ongoing prospective multicenter study, we provide new data on the natural history of Blau syndrome, focusing on functional status and visual outcome. We also present an update of the range of different NOD2 mutations found in Blau syndrome as well as recent data on morphologic and immunohistochemical characteristics of the Blau granuloma. Finally, emerging insights into pathogenic mechanisms including activation of NOD2 signal transduction, and potential biomarkers of disease activity are discussed.
Keywords: Blau syndrome; Granulomatous diseases; NOD2; RIP2 kinase; Sarcoidosis; Uveitis.
Figures
Figure 1
Exuberant ‘boggy’ synovitis of wrist in a child with Blau syndrome.
Figure 2
Tenosynovial swelling affecting tibialis posterior and peroneal tendons in Blau syndrome.
Figure 3
Tan colored “dirty” mildly scaly (late) rash.
Figure 4
Granulomatous dermatitis. Inflammatory infiltrate of the subpapilar dermis with typical multinucleated giant cells within a non-caseating epithelioid cell Blau granuloma.
Figure 5
Distribution of visual acuity in a cohort of 22 patients with Blau syndrome associated uveitis after an average follow up of 12.5 years. Visual acuity was converted into logMAR units by calculating the –Log of the visual acuity in decimal Snellen scale in meters.
Figure 6
Distribution of NOD 2 mutations in 82 patients of the International Blau registry (6).
Figure 7
Morphological and immunohistochemical characteristics of Blau granulomas. Brown colour denotes positive cytokine staining. A (top left). H & E staining showing prominent lymphocyte corona, emperipoletic lymphocytes, and multinucleated giant cell death with fragmented cytoplasm and pycnotic nuclei. Using immunohistochmistry dense staining was observed for IFN-γ (B, top right, low magnification showing several granulomas), IL-6 (C, bottom left, single granuloma showing predominant staining in corona) and IL-17 (D, bottom right, single granuloma with giant cell in center showing strong Il-17 staining).
Figure 8
Schematic representation of the NOD2 signaling pathway. Upon binding of its natural ligand (MDP), the NOD2 protein unfolds and oligomerizes through the NACT domain. This is followed by recruitment of RIP2 kinase protein through CARD-CARD interactions and activation of downstream transcriptional factors (NF-κB and MAP kinase) and secretion of inflammatory cytokines.
Similar articles
- A sporadic case of granulomatous disease negative for NOD2 mutations and mimicking Blau syndrome.
Oda F, Murakami M, Hanakawa Y, Tohyama M, Nakano N, Nishikomori R, Kambe N, Sayama K. Oda F, et al. Clin Exp Dermatol. 2018 Jan;43(1):57-58. doi: 10.1111/ced.13217. Epub 2017 Oct 30. Clin Exp Dermatol. 2018. PMID: 29082556 No abstract available. - Brief Report: First Identification of Intrafamilial Recurrence of Blau Syndrome due to Gonosomal NOD2 Mosaicism.
Mensa-Vilaro A, Cham WT, Tang SP, Lim SC, González-Roca E, Ruiz-Ortiz E, Ariffin R, Yagüe J, Aróstegui JI. Mensa-Vilaro A, et al. Arthritis Rheumatol. 2016 Apr;68(4):1039-44. doi: 10.1002/art.39519. Arthritis Rheumatol. 2016. PMID: 26606664 - Blau Syndrome With Delayed Cutaneous Manifestations: A Case Report.
Panah E, Garfield E, Zahirsha Z, Muhlbauer A, Lake E, Speiser J. Panah E, et al. Am J Dermatopathol. 2024 Jun 1;46(6):381-382. doi: 10.1097/DAD.0000000000002715. Epub 2024 Apr 23. Am J Dermatopathol. 2024. PMID: 38648024 - Blau syndrome, clinical and genetic aspects.
Sfriso P, Caso F, Tognon S, Galozzi P, Gava A, Punzi L. Sfriso P, et al. Autoimmun Rev. 2012 Nov;12(1):44-51. doi: 10.1016/j.autrev.2012.07.028. Epub 2012 Aug 2. Autoimmun Rev. 2012. PMID: 22884558 Review. - Blau syndrome revisited.
Rose CD, Martin TM, Wouters CH. Rose CD, et al. Curr Opin Rheumatol. 2011 Sep;23(5):411-8. doi: 10.1097/BOR.0b013e328349c430. Curr Opin Rheumatol. 2011. PMID: 21788900 Review.
Cited by
- The hidden base of the iceberg: gut peptidoglycome dynamics is foundational to its influence on the host.
Wheeler R, Gomperts Boneca I. Wheeler R, et al. Gut Microbes. 2024 Jan-Dec;16(1):2395099. doi: 10.1080/19490976.2024.2395099. Epub 2024 Sep 6. Gut Microbes. 2024. PMID: 39239828 Free PMC article. Review. - Proteomic Profiling of Tears in Blau Syndrome Patients in Identification of Potential Disease Biomarkers.
Galozzi P, Bindoli S, Baggio C, Battisti I, Leonardi A, Basso D, Arrigoni G, Sfriso P. Galozzi P, et al. Int J Mol Sci. 2024 Aug 1;25(15):8387. doi: 10.3390/ijms25158387. Int J Mol Sci. 2024. PMID: 39125957 Free PMC article. - Structure-activity relationship in NOD2 agonistic muramyl dipeptides.
Kamboj A, Patil MT, Petrovsky N, Salunke DB. Kamboj A, et al. Eur J Med Chem. 2024 May 5;271:116439. doi: 10.1016/j.ejmech.2024.116439. Epub 2024 Apr 20. Eur J Med Chem. 2024. PMID: 38691886 Review. - Late-Onset Panuveitis in a Chinese Girl with Sporadic Blau Syndrome: A Case Report.
Ma Z, Gao X, Zhu S. Ma Z, et al. Case Rep Ophthalmol. 2024 Apr 24;15(1):388-393. doi: 10.1159/000536005. eCollection 2024 Jan-Dec. Case Rep Ophthalmol. 2024. PMID: 38660583 Free PMC article. - Intravitreal Fluocinolone Acetonide 0.19 mg Implant in a Patient with Resistant Blau Syndrome: A Case Report.
Saigal K, Maleki A. Saigal K, et al. Case Rep Ophthalmol. 2024 Jan 19;15(1):63-70. doi: 10.1159/000535984. eCollection 2024 Jan-Dec. Case Rep Ophthalmol. 2024. PMID: 38250196 Free PMC article.
References
- Blau EB. Familial granulomatous arthritis, iritis, and rash. J Pediatr. 1985;107:689–693. - PubMed
- Jabs DA, Houk JL, Bias WB, Arnett FC. Familial granulomatous synovitis, uveitis, and cranial neuropathies. Am J Med. 1985;78:801–804. - PubMed
- Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Hafner R, Chamaillard M, Zouali H, Thomas G, Hugot JP. CARD15 mutations in Blau syndrome. Nat Genet. 2001;29:19–20. - PubMed
- Kanazawa N, Matsushima S, Kambe N, Tachibana T, Nagai S, Miyachi Y. Presence of a sporadic case of systemic granulomatosis syndrome with a CARD15 mutation. J Invest Dermatol. 2004;122:851–852. - PubMed
- Rose CD, Doyle TM, McIlvain-Simpson G, Coffman JE, Rosenbaum JT, Davey MP, Martin TM. Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. J Rheumatol. 2005;32:373–375. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical